Intranasal Naloxone for Opioid Overdose
Date Added:
January 3, 2024
Journal/Publication:
JAMA
Publisher:
American Medical Association
Publication Date:
December 21, 2023
Type:
Meta-analyses, Reviews, and Guidelines
Format:
Article
DOI (1):
10.1001/jama.2023.23248
PMID (1):
38127361
Abstract
In 2021, opioid overdose deaths exceeded 80 000 in the US.1 Naloxone, a competitive opioid receptor antagonist that reverses symptoms of opioid intoxication and overdose by displacing opioids from μ-opioid receptors, is a safe and effective medication for preventing opioid overdose death. Naloxone meets US Food and Drug Administration (FDA) criteria for approval without a prescription: its benefits outweigh risks, it treats a condition that can be identified by people in the community, it has a low potential for misuse, and it can be labeled to facilitate correct administration.
Text Availability
Commercial full text (fees may apply)
RPR Commentary
A summary of intranasal naloxone for treatment of opioid overdose. James W. Mold, MD, MPH